Illumina defends $7.1 bln Grail buy to fend off antitrust regulators | Reuters

U.S. life sciences company Illumina Inc on Tuesday defended its $7.1 billion acquisition of biotech firm Grail Inc , pledging to keep selling its …

Continue

Do you trust this headline?

Based on recent headline ratings, 88% of this readership currently trusts the local media, which has an average score of 84% regionally and is currently trending positive.

88%

Media Trust Score88%

Read All

In

City, San Diego